JP2007507538A5 - - Google Patents

Download PDF

Info

Publication number
JP2007507538A5
JP2007507538A5 JP2006534206A JP2006534206A JP2007507538A5 JP 2007507538 A5 JP2007507538 A5 JP 2007507538A5 JP 2006534206 A JP2006534206 A JP 2006534206A JP 2006534206 A JP2006534206 A JP 2006534206A JP 2007507538 A5 JP2007507538 A5 JP 2007507538A5
Authority
JP
Japan
Prior art keywords
pharmaceutical preparation
conopeptide
effective amount
pharmaceutical
analgesic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2006534206A
Other languages
English (en)
Other versions
JP2007507538A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2004/032559 external-priority patent/WO2005032556A1/en
Publication of JP2007507538A publication Critical patent/JP2007507538A/ja
Publication of JP2007507538A5 publication Critical patent/JP2007507538A5/ja
Pending legal-status Critical Current

Links

Description

発明の要約
本発明は、ω−コノペプチドと、モルヒネ、ブピバカイン、クロニジン、ハイドロモルホン、バクロフェン、クエン酸フェンタニル、ブプレノルフィンおよびクエン酸スフェンタニルからなる群から選ばれる鎮痛剤、またはその薬学的に許容される塩を含有する医薬製剤であって、該ω−コノペプチドがその効力を維持し、該鎮痛剤と物理的にも、化学的にも共存できる該医薬製剤に関する。該医薬製剤は髄腔内投与に適している。
本発明は、また疼痛軽減方法を提供する。該方法は、主体にω−コノペプチド、好ましくはジコノチドを、モルヒネ、ブピバカイン、クロニジン、ハイドロモルホン、バクロフェン、クエン酸フェンタニル、ブプレノルフィンおよびクエン酸スフェンタニルからなる群から選ばれる鎮痛剤、またはその薬学的に許容される塩と共に投与するステップを含み、該ω−コノペプチドがその効力を維持し、該鎮痛剤と物理的にも、化学的にも共存できる。好ましい投与経路は、髄腔内投与、特に継続的髄腔内注入である。
他の1つの態様として、疼痛を軽減させる方法は、ω−コノペプチドの有効量と、ブピバカイン、クロニジンおよびバクロフェンからなる群から選択される鎮痛剤またはその薬学的に許容される塩の有効量を、患者に投与するステップを含み、その際の該投与法は継続髄腔内注入である。好ましいω−コノペプチドは、ジコノチドである。ω−コノペプチドとその鎮痛剤は互いに別々の製剤でよく、そして同時に或いは連続して投与されうる。別にω−コノペプチドとその鎮痛剤は、予め混合し、投与用の1つの製剤を形成しうる。
Figure 2007507538

Claims (14)

  1. ω−コノペプチド、抗酸化剤、および、モルヒネ、ブピバカイン、クロニジン、ハイドロモルホン、バクロフェン、フェンタニル、スフェンタニルおよびブプレノルフィンからなる群から選ばれる鎮痛剤またはその薬学的に許容される塩を含有する医薬製剤であって、該ω−コノペプチドがその有効性を維持し、該鎮痛剤と物理的にも、化学的にも共存できる該医薬製剤。
  2. 該ω−コノペプチドがジコノチドである請求項1に記載の医薬製剤
  3. 該医薬製剤が髄腔内投与に適した医薬製剤である請求項1に記載の医薬製剤。
  4. 該医薬製剤が継続的髄腔内注入に適した医薬製剤である請求項3に記載の医薬製剤。
  5. 該医薬製剤が薬剤投与用植込み式ポンプ中37℃で少なくとも7日間安定である請求項1に記載の医薬製剤。
  6. 該鎮痛剤がモルヒネ、クロニジン、ハイドロモルホン、フェンタニルまたはスフェンタニルである請求項1から5のいずれかに記載の医薬製剤。
  7. 該鎮痛剤がバクロフェンまたはブピバカインである請求項1から5のいずれかに記載の医薬製剤。
  8. 患者の疼痛を軽減するための医薬製剤であって、該医薬製剤がω−コノペプチドの有効量、抗酸化剤、および、ハイドロモルホン、ブプレノルフィン、フェンタニルおよびスフェンタニルからなる群から選ばれる鎮痛剤またはその薬学的に許容される塩の有効量を含有する医薬製剤
  9. 患者の疼痛を軽減するための医薬製剤であって、該医薬製剤がω−コノペプチドの有効量、抗酸化剤、および、ブピバカイン、クロニジンおよびバクロフェンからなる群から選ばれる鎮痛剤またはその薬学的に許容される塩の有効量を含有する医薬製剤
  10. 患者の疼痛を軽減するための医薬製剤であって、該医薬製剤がω−コノペプチドの有効量、抗酸化剤、およびモルヒネまたはその薬学的に許容される塩の有効量を含有する医薬製剤。
  11. 髄腔内アヘン誘導肉芽腫形成に敏感な患者の疼痛を軽減するための医薬製剤であって、該医薬製剤がω−コノペプチドを含有する医薬製剤
  12. 該医薬製剤が、更にブピバカイン、クロニジンおよびバクロフェンからなる群から選ばれる鎮痛剤またはその薬学的に許容される塩の有効量を含有する請求項11に記載の医薬製剤
  13. 該ω−コノペプチドがジコノチドである請求項8から12のいずれかに記載の医薬製剤。
  14. 該医薬製剤が、10−25μg/mlのジコノチドおよび7.5−18.75mg/mlのモルヒネを含有する請求項10に記載の医薬製剤
JP2006534206A 2003-10-02 2004-10-01 疼痛軽減方法 Pending JP2007507538A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US50862503P 2003-10-02 2003-10-02
US50846903P 2003-10-03 2003-10-03
PCT/US2004/032559 WO2005032556A1 (en) 2003-10-02 2004-10-01 Method for reducing pain

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2011129404A Division JP2011173931A (ja) 2003-10-02 2011-06-09 疼痛軽減方法

Publications (2)

Publication Number Publication Date
JP2007507538A JP2007507538A (ja) 2007-03-29
JP2007507538A5 true JP2007507538A5 (ja) 2007-11-08

Family

ID=34426056

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2006534206A Pending JP2007507538A (ja) 2003-10-02 2004-10-01 疼痛軽減方法
JP2011129404A Pending JP2011173931A (ja) 2003-10-02 2011-06-09 疼痛軽減方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2011129404A Pending JP2011173931A (ja) 2003-10-02 2011-06-09 疼痛軽減方法

Country Status (5)

Country Link
US (14) US7268109B2 (ja)
EP (1) EP1689401A1 (ja)
JP (2) JP2007507538A (ja)
CA (2) CA2930900C (ja)
WO (1) WO2005032556A1 (ja)

Families Citing this family (80)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6057287A (en) 1994-01-11 2000-05-02 Dyax Corp. Kallikrein-binding "Kunitz domain" proteins and analogues thereof
US7153829B2 (en) 2002-06-07 2006-12-26 Dyax Corp. Kallikrein-inhibitor therapies
ATE477020T1 (de) 2002-06-07 2010-08-15 Dyax Corp Prevention und verringerung von ischemia
JP2005537006A (ja) 2002-08-28 2005-12-08 ダイアックス、コープ 臓器及び組織の保存方法
EP1689401A1 (en) 2003-10-02 2006-08-16 Elan Pharmaceuticals, Inc. Method for reducing pain
US7235530B2 (en) 2004-09-27 2007-06-26 Dyax Corporation Kallikrein inhibitors and anti-thrombolytic agents and uses thereof
US20060210692A1 (en) * 2005-03-18 2006-09-21 Mower Thomas E Baby food composition
US20060210688A1 (en) * 2005-03-18 2006-09-21 Mower Thomas E Dehydrated sports drink powder
US20060210496A1 (en) * 2005-03-18 2006-09-21 Mower Thomas E Compositions for skin protection from ultraviolet damage
US7666448B2 (en) * 2005-03-18 2010-02-23 Sakura Properties, Llc Skin cleansing article
US20060210697A1 (en) * 2005-03-18 2006-09-21 Mower Thomas E Infant formula composition
US20070020358A1 (en) * 2005-03-18 2007-01-25 Mower Thomas E Sports drink concentrate
US7749545B2 (en) * 2005-03-18 2010-07-06 Sakura Properties, Llc Fucoidan compositions and methods for dietary and nutritional supplements
US7776365B2 (en) * 2005-03-18 2010-08-17 Sakura Properties, Llc Article with skin protecting and moisturizing compound
WO2006110853A2 (en) * 2005-04-12 2006-10-19 Maren Alianna J System and method for evidence accumulation and hypothesis generation
US8252329B2 (en) 2007-01-05 2012-08-28 Acelrx Pharmaceuticals, Inc. Bioadhesive drug formulations for oral transmucosal delivery
US8865743B2 (en) 2006-01-06 2014-10-21 Acelrx Pharmaceuticals, Inc. Small volume oral transmucosal dosage forms containing sufentanil for treatment of pain
US8202535B2 (en) 2006-01-06 2012-06-19 Acelrx Pharmaceuticals, Inc. Small-volume oral transmucosal dosage forms
US8535714B2 (en) 2006-01-06 2013-09-17 Acelrx Pharmaceuticals, Inc. Small volume oral transmucosal dosage forms containing sufentanil for treatment of pain
JP2009523802A (ja) * 2006-01-17 2009-06-25 リージェンツ オブ ザ ユニバーシティー オブ コロラド Cns状態のための治療剤の安定製剤の中枢投与
US8536445B2 (en) * 2006-06-02 2013-09-17 Emcore Solar Power, Inc. Inverted metamorphic multijunction solar cells
US20080102097A1 (en) * 2006-10-31 2008-05-01 Zanella John M Device and method for treating osteolysis using a drug depot to deliver an anti-inflammatory agent
DK2604257T3 (en) * 2007-08-07 2017-08-28 Acelrx Pharmaceuticals Inc ORAL TRANSMUCOSAL DOSAGE FORMS INCLUDING SUFENTANIL AND TRIAZOLAM
CA2695012A1 (en) * 2007-08-23 2009-02-26 Genzyme Corporation Treatment with kallikrein inhibitors
US8470360B2 (en) 2008-04-18 2013-06-25 Warsaw Orthopedic, Inc. Drug depots having different release profiles for reducing, preventing or treating pain and inflammation
CN101412752B (zh) * 2007-12-26 2011-12-07 杭州诺泰制药技术有限公司 齐考诺肽的固相合成方法
US8420114B2 (en) * 2008-04-18 2013-04-16 Warsaw Orthopedic, Inc. Alpha and beta adrenergic receptor agonists for treatment of pain and / or inflammation
US20090264477A1 (en) * 2008-04-18 2009-10-22 Warsaw Orthopedic, Inc., An Indiana Corporation Beta adrenergic receptor agonists for treatment of pain and/or inflammation
US8956641B2 (en) * 2008-04-18 2015-02-17 Warsaw Orthopedic, Inc. Alpha adrenergic receptor agonists for treatment of inflammatory diseases
US8722079B2 (en) 2008-04-18 2014-05-13 Warsaw Orthopedic, Inc. Methods for treating conditions such as dystonia and post-stroke spasticity with clonidine
US9132119B2 (en) 2008-04-18 2015-09-15 Medtronic, Inc. Clonidine formulation in a polyorthoester carrier
US9132085B2 (en) 2008-04-18 2015-09-15 Warsaw Orthopedic, Inc. Compositions and methods for treating post-operative pain using clonidine and bupivacaine
US9610243B2 (en) 2008-04-18 2017-04-04 Warsaw Orthopedic, Inc. Clonidine compounds in a biodegradable polymer
US8946277B2 (en) * 2008-04-18 2015-02-03 Warsaw Orthopedic, Inc. Clonidine formulations in a biodegradable polymer carrier
US8889173B2 (en) * 2008-04-18 2014-11-18 Warsaw Orthopedic, Inc. Alpha adrenergic receptor agonists for treatment of pain and/or inflammation
US20090263489A1 (en) * 2008-04-18 2009-10-22 Warsaw Orthopedic, Inc. Analgesic and anti-inflammatory compositions and methods for reducing, preventing or treating pain and inflammation
USRE48948E1 (en) 2008-04-18 2022-03-01 Warsaw Orthopedic, Inc. Clonidine compounds in a biodegradable polymer
US20090264489A1 (en) * 2008-04-18 2009-10-22 Warsaw Orthopedic, Inc. Method for Treating Acute Pain with a Formulated Drug Depot in Combination with a Liquid Formulation
US8883768B2 (en) * 2008-04-18 2014-11-11 Warsaw Orthopedic, Inc. Fluocinolone implants to protect against undesirable bone and cartilage destruction
US9072727B2 (en) * 2008-04-18 2015-07-07 Warsaw Orthopedic, Inc. Alpha adrenergic receptor agonists for treatment of degenerative disc disease
US8629172B2 (en) * 2008-04-18 2014-01-14 Warsaw Orthopedic, Inc. Methods and compositions for treating post-operative pain comprising clonidine
US20090263451A1 (en) * 2008-04-18 2009-10-22 Warsaw Orthopedic, Inc. Anti-Inflammatory and/or Analgesic Agents for Treatment of Myofascial Pain
US8557273B2 (en) * 2008-04-18 2013-10-15 Medtronic, Inc. Medical devices and methods including polymers having biologically active agents therein
US20110129508A1 (en) * 2008-05-06 2011-06-02 Relevare Aust. Pty Ltd Methods and compositions for the management of pain using omega-conotoxins
US20110171163A1 (en) * 2008-09-19 2011-07-14 Nektar Therapeutics Polymer conjugates of ziconotide peptides
EP2350118B1 (en) 2008-09-19 2016-03-30 Nektar Therapeutics Carbohydrate-based drug delivery polymers and conjugates thereof
US20100098746A1 (en) * 2008-10-20 2010-04-22 Warsaw Orthopedic, Inc. Compositions and methods for treating periodontal disease comprising clonidine, sulindac and/or fluocinolone
US8945592B2 (en) 2008-11-21 2015-02-03 Acelrx Pharmaceuticals, Inc. Sufentanil solid dosage forms comprising oxygen scavengers and methods of using the same
US8822546B2 (en) * 2008-12-01 2014-09-02 Medtronic, Inc. Flowable pharmaceutical depot
EP2385843A4 (en) 2009-01-06 2013-02-27 Dyax Corp TREATMENT OF MUZOSITIS WITH CALLICINE INHIBITORS
US20100228097A1 (en) * 2009-03-04 2010-09-09 Warsaw Orthopedic, Inc. Methods and compositions to diagnose pain
US20100239632A1 (en) * 2009-03-23 2010-09-23 Warsaw Orthopedic, Inc. Drug depots for treatment of pain and inflammation in sinus and nasal cavities or cardiac tissue
PL387984A1 (pl) * 2009-05-07 2010-11-08 Instytut Medycyny Doświadczalnej I Klinicznej Im. Mirosława Mossakowskiego Pan Nowe kompozycje substancji leczniczych do leczenia bólów przewlekłych
US8617583B2 (en) * 2009-07-17 2013-12-31 Warsaw Orthopedic, Inc. Alpha adrenergic receptor agonists for prevention or treatment of a hematoma, edema, and/or deep vein thrombosis
US8231891B2 (en) * 2009-07-31 2012-07-31 Warsaw Orthopedic, Inc. Implantable drug depot for weight control
US20110091544A1 (en) * 2009-10-16 2011-04-21 Acelrx Pharmaceuticals, Inc. Compositions and Methods for Mild Sedation, Anxiolysis and Analgesia in the Procedural Setting
US20110097375A1 (en) 2009-10-26 2011-04-28 Warsaw Orthopedic, Inc. Formulation for preventing or reducing bleeding at a surgical site
CA3168591A1 (en) 2010-01-06 2011-07-14 Takeda Pharmaceutical Company Limited Plasma kallikrein binding proteins
DE102010053416A1 (de) 2010-12-03 2012-06-06 Friedrich-Schiller-Universität Jena Verfahren zur Synthese von Cystein-haltigen Peptiden durch Native Chemische Ligation und/oder Oxidation
JP2014506257A (ja) 2011-01-06 2014-03-13 ダイアックス コーポレーション 血漿カリクレイン結合タンパク質
JP2013037571A (ja) 2011-08-09 2013-02-21 Sony Corp 情報処理装置、情報処理方法、プログラム、及び情報処理システム
US9180108B2 (en) 2011-10-27 2015-11-10 Medtronic, Inc. Baclofen formulations and methods for making same
US9155734B2 (en) 2012-03-07 2015-10-13 Mallinckrodt Llc Stability of hydromorphone hydrochloride solutions
WO2014089209A2 (en) 2012-12-04 2014-06-12 Abbvie, Inc. Blood-brain barrier (bbb) penetrating dual specific binding proteins
EP2948475A2 (en) 2013-01-23 2015-12-02 AbbVie Inc. Methods and compositions for modulating an immune response
US20140296830A1 (en) * 2013-03-28 2014-10-02 Jazz Pharmaceuticals, Inc. Methods of administering drugs in an implantable multi-chamber pump
JP6246640B2 (ja) * 2014-03-25 2017-12-13 京セラ株式会社 電子機器
KR102555955B1 (ko) 2014-03-27 2023-07-18 다케다 파머수티컬 컴패니 리미티드 당뇨병성 황반 부종의 치료를 위한 조성물 및 방법
BR102015010089A2 (pt) * 2015-05-04 2017-07-18 Ministério Da Ciência E Tecnologia Process for obtaining a product for prevention, paralysis of care injuries and remineralization of teeth and obtained product
US10519324B2 (en) 2015-05-22 2019-12-31 Clemson University Research Foundation Conotoxin peptides for use in biofouling deterrence
EP3387018A1 (en) 2015-12-11 2018-10-17 Dyax Corp. Plasma kallikrein inhibitors and uses thereof for treating hereditary angioedema attack
US11504347B1 (en) 2016-07-22 2022-11-22 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11602512B1 (en) 2016-07-22 2023-03-14 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
UY37341A (es) 2016-07-22 2017-11-30 Flamel Ireland Ltd Formulaciones de gamma-hidroxibutirato de liberación modificada con farmacocinética mejorada
US11986451B1 (en) 2016-07-22 2024-05-21 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11602513B1 (en) 2016-07-22 2023-03-14 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US10369157B1 (en) 2018-03-29 2019-08-06 Mfkc 200, Llc Multi-agent formulation
WO2020178695A1 (en) 2019-03-01 2020-09-10 Flamel Ireland Limited Gamma-hydroxybutyrate compositions having improved pharmacokinetics in the fed state
US11779557B1 (en) 2022-02-07 2023-10-10 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11583510B1 (en) 2022-02-07 2023-02-21 Flamel Ireland Limited Methods of administering gamma hydroxybutyrate formulations after a high-fat meal

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8626098D0 (en) * 1986-10-31 1986-12-03 Euro Celtique Sa Controlled release hydromorphone composition
US5559095A (en) * 1989-11-22 1996-09-24 Neurex Corporation Delayed treatment method of reducing ischemia-related neuronal damage
US5051403A (en) * 1989-11-22 1991-09-24 Neurex Corporation Method of treating ischemia-related neuronal damage
US5189020A (en) * 1989-11-22 1993-02-23 Neurex Corporation Method of reducing neuronal damage using omega conotoxin peptides
ATE165977T1 (de) * 1991-12-30 1998-05-15 Neurex Corp Methoden zur erzeugung von analgesie und zur verstärkung von opiat-analgesie
US5824645A (en) * 1991-12-30 1998-10-20 Neurex Corporation Method of treating inflammation
US5471033A (en) * 1994-04-15 1995-11-28 International Business Machines Corporation Process and apparatus for contamination-free processing of semiconductor parts
WO1996024330A1 (en) * 1995-02-10 1996-08-15 Medtronic, Inc. Method and device for administering analgesics
US6054429A (en) * 1996-03-08 2000-04-25 Elan Pharmaceuticals, Inc. Epidural method of producing analgesia
US5795864A (en) * 1995-06-27 1998-08-18 Neurex Corporation Stable omega conopetide formulations
DE69637021T2 (de) 1995-06-27 2008-01-10 Eisai R&D Management Co., Ltd. Zusammensetzungen zur Erzielung von Analgesie und zur Hemmung der Progression neuropathischer Schmerzerkrankungen
US6379882B1 (en) * 1998-09-14 2002-04-30 Elan Pharmaceuticals, Inc. Method for selecting compounds for treating ischemia-related cellular damage
US20010036943A1 (en) * 2000-04-07 2001-11-01 Coe Jotham W. Pharmaceutical composition for treatment of acute, chronic pain and/or neuropathic pain and migraines
WO2001083555A2 (en) * 2000-05-04 2001-11-08 California Institute Of Technology Pain signaling molecules
US20030232871A1 (en) * 2002-03-15 2003-12-18 Sheikh Ahmad Y. Crystalline parecoxib sodium
EP1689401A1 (en) 2003-10-02 2006-08-16 Elan Pharmaceuticals, Inc. Method for reducing pain
US20140296830A1 (en) * 2013-03-28 2014-10-02 Jazz Pharmaceuticals, Inc. Methods of administering drugs in an implantable multi-chamber pump

Similar Documents

Publication Publication Date Title
JP2007507538A5 (ja)
JP6212104B2 (ja) オピエートアゴニスト及びアゴニスト−アンタゴニストの乱用抑止性経皮製剤
Pascoe Opioid analgesics
US20180064706A1 (en) Abuse-resistant mucoadhesive devices for delivery of buprenorphine
DK2574167T3 (en) LIQUID NOSE SPRAY CONTAINING low-dose naltrexone
US20070116730A1 (en) Pharmaceutical compositions
JP2005512995A5 (ja)
JP2005515966A5 (ja)
CA2661759A1 (en) Buprenophine-wafer for drug substitution therapy
JP2012505883A5 (ja)
WO2011098539A1 (en) Treatment of loss of sense of touch with saxitoxin derivatives
US20180200182A1 (en) Transmucosal drug delivery devices for use in chronic pain relief
CH708257B1 (de) Zusammensetzung zur Behandlung einer Opioid-induzierten unerwünschten pharmakodynamischen Reaktion.
EP3331509A1 (en) Stable liquid injectable solution of midazolam and pentazocine
JP2022516595A (ja) オピオイドアンタゴニストを送達するための組成物及び方法
JP2007008871A (ja) 経皮吸収促進組成物
JP2012516288A (ja) 薬物乱用抑制剤、方法および組成物
US10736874B1 (en) Methods for treating pain associated with sickle cell disease
JP2004043479A (ja) 経鼻吸収用組成物
CA3130619C (en) Naloxone formulations for sublingual and/or buccal administration
WO2008062453B1 (en) Composition containing nicotine base aromatic oils and alkyl salicylate for the delivery of nicotine base in vapour form
AU2011254554B2 (en) Liquid nasal spray containing low-dose naltrexone
KR20210003313A (ko) 만성 통증 완화에 이용되는 점막 관통 약물 전달 장치
JP2009510158A (ja) 毒物依存症の治療におけるネボグラミンの使用
JP2021536443A (ja) 高血圧治療をサーカディアンリズムと同期させる